CJC-1295: What the peptide is and why it's so central

Among peptides studied in growth-hormone-related research, CJC-1295 is one of the most central names. As a GHRH analog, it has an entirely distinct mechanism of action compared to other substances in the same research field, which has made it a staple building block in many combined protocols. Here we go through why.

What is CJC-1295?

CJC-1295 is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone) – the body's own signaling substance for initiating growth hormone release. Unlike GH secretagogues that act via the ghrelin receptor, CJC-1295 binds directly to the GHRH receptor in the pituitary gland, making it a key substance for researchers who want to study this specific signaling pathway.

Why is CJC-1295 so talked about?

The variant we offer, CJC-1295 without DAC (Drug Affinity Complex), is studied for a shorter half-life than the DAC variant, making it particularly suited to research protocols aiming to mimic the body's natural, pulsatile GH release rather than a constantly elevated level. It's exactly this controllability that has made CJC-1295 (NO DAC) the first choice among researchers in the field.

How CJC-1295 works in research

In preclinical studies, CJC-1295 has been examined for its ability to bind to the GHRH receptor and thereby stimulate the pituitary gland to release growth hormone. As with all research at this stage, results are study-specific and should be interpreted in their scientific context.

CJC-1295 and Ipamorelin

CJC-1295 is often combined in research settings with Ipamorelin, a GH secretagogue that acts via a completely different receptor – the ghrelin receptor. By combining the two mechanisms in the same protocol, the effect on GH release is studied as more pronounced than with either peptide alone. We offer both separately, as well as a ready-made CJC-1295 (NO DAC) + Ipamorelin combination for those researching a combined protocol.

Administration

In research settings, CJC-1295 is usually administered via subcutaneous injection. The peptide is supplied as a freeze-dried powder and is easily reconstituted with bacteriostatic water before use. An insulin syringe with a fine needle is used for precise dosing during injection.

Dosing in research contexts

Dosing ranges found in published research vary depending on study design. CJC-1295 is sold by us exclusively as a product intended for laboratory and research purposes – not for human consumption – and we therefore don't provide a specific dosing recommendation here. Always base your approach on the research protocol and scientific literature relevant to your specific purpose.

Why choose CJC-1295 from SveaPeptid?

In hormonal research, purity is absolutely critical – the smallest deviation can affect the result. Our CJC-1295 (NO DAC) 10mg is tested by an independent third-party laboratory, and we publish a certificate of analysis (COA) for every batch. With fast, discreet delivery and free shipping over 899 kr, we make it easy to keep your protocol on track.

Summary

CJC-1295 is one of the most central GHRH analogs in growth hormone research, valued for its precise action via the GHRH receptor and for how well it complements GH secretagogues like Ipamorelin. Purity, correct storage and careful handling are crucial for reliable research results – which is exactly what we deliver with every batch.

Ready to get started? Explore our lab-tested CJC-1295 (NO DAC) 10mg with free shipping over 899 kr, or see our full range in the Growth category.